Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Aging populations coupled with improved outcomes for many chronic medical conditions has led to increases in AF diagnoses. AF is also known to be associated with an increased risk of adverse events such as transient ischemic attack, ischemic stroke, systemic embolism, and death. This association is enhanced in select populations with preexisting comorbid conditions such as chronic heart failure. The aim of this review is to highlight the advances in the field of cardiology in the management of AF in both acute and long-term settings. We will also review the evolution of anticoagulation management over the past few years and landmark trials in the development of novel oral anticoagulants (NOACs), reversal agents for new NOACs, nonpharmacological options to anticoagulation therapy, and the role of implantable loop recorder in AF management.
Interest in omega-3 has grown dramatically since the observation that Eskimos have a high level of omega-3 due to high fish consumption that was associated with a low incidence of myocardial infarction. This was thought to be related to its antithrombotic effect due to inhibition of platelet aggregation. Subsequently, several studies indicated a potential beneficial impact of omega-3 in the treatment and prevention of cardiovascular disease including chronic heart failure (CHF) especially in patients with reduced ejection fraction. Despite the progress in the medical and device management of CHF, a significant number of patients with this clinical syndrome do not respond to current therapy. In addition, CHF remains a condition of a high morbidity, hospitalization and mortality. Therefore, clinicians got interested in exploring any potential benefit in the care of patients with CHF. Potential benefits of omega-3 in the management of CHF patients have been evaluated and showed possible positive effect on the progression of CHF through several mechanisms. These include the improvement of endothelial function, reduction of vascular tone, reduction of platelet aggregability, and improvement of myocardial function. This review article cites data from several experiments pertaining to the benefits of omega-3 in patients with CHF. The aim is to review the mechanisms, potential benefits, and possible therapeutic implications of omega-3 in patients with CHF. Results show that there is a significant difference in patients who intake omega-3 versus those who do not. This article is proof that there are other methods to treating CHF than what is prescribed in modern medicine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.